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Abstract
Background: Dispersal of glioblastoma (GBM) cells leads to recurrence and poor prognosis. Accordingly, molecular
pathways involved in dispersal are potential therapeutic targets. The mitogen activated protein kinase/extracellular
signal regulated kinase (MAPK/ERK) pathway is commonly dysregulated in GBM, and targeting this pathway with
MEK inhibitors has proven effective in controlling tumor growth. Since this pathway also regulates ECM remodeling
and actin organization − processes crucial to cell adhesion, substrate attachment, and cell motility – the aim of this
study was to determine whether inhibiting this pathway could also impede dispersal.
Methods: A variety of methods were used to quantify the effects of the MEK inhibitor, PD0325901, on potential
regulators of dispersal. Cohesion, stiffness and viscosity were quantified using a method based on ellipsoid
relaxation after removal of a deforming external force. Attachment strength, cell motility, spheroid dispersal velocity,
and 3D growth rate were quantified using previously described methods.
Results: We show that PD0325901 significantly increases aggregate cohesion, stiffness, and viscosity but only when
tumor cells have access to high concentrations of fibronectin. Treatment also results in reorganization of actin from
cortical into stress fibers, in both 2D and 3D culture. Moreover, drug treatment localized pFAK at sites of cell-substratum
adhesion. Collectively, these changes resulted in increased strength of substrate attachment and decreased motility, a
decrease in aggregate dispersal velocity, and in a marked decrease in growth rate of both 2D and 3D cultures.
Conclusions: Inhibition of the MAPK/ERK pathway by PD0325901 may be an effective therapy for reducing dispersal
and growth of GBM cells.
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Background
Early and continuing dispersal of tumor cells from the
primary mass renders GBM refractory to complete sur-
gical excision or targeted chemotherapy and directly
leads to recurrence and dismal prognosis. Strategies
aimed at containing the primary or recurrent tumor
could significantly improve targeted delivery of chemo-
therapeutic agents and increase the likelihood of total
surgical resection. To disperse, cells must first detach
from the primary mass, a process that likely involves
mechanisms that decrease cohesion between tumor cells
[1]. Cells must also attach to substrates at strengths that
optimize their motility and secrete factors to facilitate
their interaction with parenchyma [2, 3]. In addition,
tumor cells must also become relatively compliant so as
to deform and “squeeze” through pores in a meshwork
of ECM components [4], and in the case of GBM, astro-
cytes within the normal brain parenchyma. Accordingly,
strategies aimed at preventing tumor cell detachment,
limiting motility, and inhibiting changes in compliance
offer an effective approach to reduce dispersal. Ideally,
such strategies should employ pharmacological agents
that can cross the blood–brain barrier and that specific-
ally target molecular pathways involved in mediating co-
hesion, adhesion, and compliance.
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Cadherins, integrins and the extracellular matrix
(ECM) are potential therapeutic targets, and various
studies have identified drugs that can modulate their ex-
pression or function. For example, gamma-linolenic acid
(GLA) up-regulates E-cadherin expression and inhibits
invasion of lung, colon, breast, melanoma, and liver can-
cer [5]. Invasion suppression here was likely due to an
increase in the strength of intercellular cohesion medi-
ated by up-regulation of E-cadherin. 5-aza-deoxycitidine
(5 AC) has also been shown to effectively inhibit inva-
sion by up-regulating E-cadherin expression [6]. Because
the down-regulation of E-cadherin is often associated
with up-regulation of N-cadherin during epithelial-
mesenchymal transition, drugs that can block N-
cadherin expression have also been shown to be effective
in blocking invasion. Biflorin, a novel o-naphtoquinone,
has been shown to inhibit expression of N-cadherin and
to block invasion of breast cancer cells [7]. Such drugs
could be of potential benefit for glioblastoma given the
correlation between increased N-cadherin expression in
high-grade gliomas and tissue invasion [8]. Various
integrins, including αvβ3 and αvβ5 have also been tar-
gets of anticancer therapy. Cilengitide, a cyclic pentapep-
tide, is a specific inhibitor of these integrins and has
been shown to have anti-invasive activity in various gli-
oma models [9]. Given the complexity and heterogeneity
of the ECM, and the likelihood that glioma cells tune
their integrin receptor fingerprint to match the local
ECM microenvironment, drugs that modulate the ECM
may prove effective in reducing dispersal. Many of these
drugs, including various corticosteroids, target the ECM
as a by-product of the drugs’ principal actions. Conse-
quently, this activity may in part be beneficial to the
drugs’ disease-modifying properties [10]. An example of
such a drug is Dexamethasone (Dex). Dex is currently
used to treat brain tumor-related edema associated with
mass effect from Glioblastoma [11]. A by-product of the
effects of Dex in glioblastoma is its ability to restore fi-
bronectin matrix assembly (FNMA) and decrease de-
tachment of tumor cells from cultured 3D spheroids [1].
However, due to the relatively high doses required, Dex
has many side-effects, often limiting its long-term use.
Identification of other drugs that can have similar effects
but more specifically target pathways involved in modu-
lating integrins and the ECM could be of therapeutic
value.
The MAPK/ERK pathway has been identified as a
commonly dysregulated pathway in several cancers,
most notably in melanoma. Combined targeting of this
pathway can have a synergistic effect in controlling
tumor growth [12]. Clinical trials using various MEK
inhibitors, such as trametinib [13, 14], cobimetinib [15]
and CI 1040 (PD184352) [16] have been shown to
shrink some melanomas, specifically those with BRAF
mutations. The MEK inhibitor PD0325901 has also
demonstrated efficacy in melanoma cell lines independent
of BRAF status [17]. Experimental models have demon-
strated in vitro and in vivo efficacy of PD0325901 in con-
trolling tumor growth in animal models of GBM [18],
although studies have identified possible issues with lim-
ited access through the blood–brain barrier [19]. To our
knowledge, there is only one ongoing phase-2 trial testing
the effects of PD0325901 on tumor growth in patients
with neurofibromatosis type −1 (NF1) or plexiform neuro-
fibromas [20] NCT02096471), and none testing efficacy in
GBM. The majority of these studies have focused mainly
on inhibition of growth and on activation of apoptosis. In-
asmuch as MEK inhibitors target pathways that can also
influence actin organization and remodeling of the ECM,
we asked whether PD0325901 could also serve to impact
mechanisms that regulate dispersal of primary human
GBM cells.
We first determined whether primary human GBM
cells used in this study are sensitive to PD0325901. We
then assessed the effects of MEK inhibition on integrin
activation vis à vis restoration of FNMA and actin
organization in both 2D and 3D cultures. We also quan-
tified the effects of PD0325901 on spheroid mechanical
properties including cohesion, stiffness and viscosity. We
evaluated effects of PD0325901 in regulating the
strength of cell-substrate adhesion, cell motility, disper-
sal of tumor cells from spheroids, and in an ex vivo dis-
persal assay. Finally, we determined whether PD0325901
could also influence the growth rate of both 2D and 3D
cultures of GBM.
Methods
Cell lines, maintenance, treatment, and generation of 3D
spheroids
Four human primary glioblastoma cell lines (GBM-1,
GBM-2, GBM-3 and GBM-4) were previously isolated
and characterized [21]. Samples were examined by a
neuropathologist and stained for several markers to con-
firm their designation as human GBM. Microscopically,
all lines were described as astrocytic neoplasms with
moderate to high pleiomorphism, vascular endothelial
hyperplasia, with areas of abundant necrosis. Lines are
all GFAP positive. GBM-1 and GBM-4 exhibit PTEN
loss and all lines appear to express p-AKT. All lines ex-
press Nestin and BMI-1, both markers of undifferenti-
ated cells. Collectively, pathologic and molecular analysis
confirms highly undifferentiated grade IV glioma/glio-
blastoma. Cells were maintained in Eagles’ Minimal
Essential Medium (EMEM)/10% fetal calf serum (FCS)
and antibiotics/antimycotics. They were sub-cultured
using standard protocols and used at 3rd to 6th passage.
Normal human astrocytes (NHA) were purchased from
Lonza (Allendale, NJ) and maintained in AGM™
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Astrocyte Growth Medium as recommended by the
manufacturer. Where required, cells were treated with
PD 0325901, a powerful inhibitor of ERK1/2 phosphoryl-
ation, at a final concentration of 1 μM w/v DMSO for
24 h prior to assay. Spheroids were generated as previ-
ously described [1].
Immunoblot and immunofluorescence assays
To confirm that PD0325901 inhibited ERK1/2 phos-
phorylation, cells were treated with either dimethyl sulf-
oxide (DMSO, vehicle control) or 1 μM PD0325901
overnight under standard tissue culture conditions.
Twenty μg of protein was separated by SDS-PAGE
under reducing conditions. Gels were blotted to PVDF
and probed with anti-phospho P44/42 MAPK or P44/42
MAPK antibodies (Cell Signaling Technologies, Danvers,
MA) and appropriate HRP-conjugated secondary anti-
bodies. Blots were developed using Amersham ECL
Prime Western Blotting Detection reagent (GE Health-
care Life Sciences, Pittsburgh, PA) and a C-Digit Blot
Scanner (Li-COR, Lincoln, NE). Assessment of FNMA,
phospho-FAK and actin expression by GBM cells in
conventional 2D culture was performed as previously
described [1]. For assessment of actin organization in
3D spheroids, aggregates of GBM cells were fixed and
permeabilized with 4% paraformaldehyde/0.5% Triton
X-100 and incubated in 6nM rhodamine-phalloidin for
30 min. Aggregates were washed 4x with PBS, mounted
onto slides, and imaged using a Zeiss AxioImager Z1
spinning disc confocal microscope attached to a Photo-
metrics Evolve 512 EMCCD camera with Metamorph
Premier imaging software.
Measurement of aggregate cohesion and viscoelasticity
Aggregate cohesion was measured by tissue surface
tensiometry (TST). TST employs a custom-built instru-
ment to compress spherical cellular aggregates between
poly-HEMA coated parallel plates to which they cannot
adhere. Measurements of aggregate geometry and re-
sistance to the applied force are then applied to the
Young-Laplace equation to calculate aggregate surface
tension. The method has been described in detail [1,
22–24]. TST measurements are only valid when tissues
behave like liquid systems [22–24]. Accordingly, the
calculated surface tension of a liquid aggregate, when
subjected to two successive compressions (σ1 and σ2),
the second greater than the first, will remain constant.
In such aggregates the ratio of σ2/σ1 will approach 1
and will be less than the ratio of the force applied at
each successive compression (F2/F1). The surface ten-
sion of liquid aggregates will also be independent of ag-
gregate size. Only measurements in which surface
tension is independent of the applied force and size
were used to calculate average σ for each cell line.
For measurement of viscoelasticity, aggregates ran-
ging in size from 200-400 μm were loaded into the
tensiometer and subjected to a compressive force for
30 s, whereupon the force was removed and aggre-
gates were allowed to relax for 2 min. A high-speed
camera captured 12 frames/s and the shape of the
relaxing aggregates was extracted and analyzed using
an in-house edge detection and analysis algorithm.
Mechanical parameters were extracted from the shape
dynamics with a continuum-based model which in-
cludes a Kelvin-Voigt bulk enclosed in a stressed sur-
face. This advanced model is different than the simple
spring-dashpot or compartmental models previously
described [25]. Analysis of the relaxation dynamics
was greatly facilitated by a closed-form, analytical so-
lution that we derived. Details of the theory and the
data analysis method, as well as preliminary data valid-
ating our approach are presented in Additional file 1.
Measurement of shear-flow induced detachment
Cell-ECM attachment was measured by subjecting ad-
hering cells to flow-induced shear stress as previously
described [1]. Briefly, DMSO or PD0325901-treated
GBM cells were plated at a concentration of 5x104 cells/
ml onto 6-well polyethylene terephthalate cell culture in-
serts (Franklin Lakes, NJ) for 2 h and were then inverted
into complete medium and incubated overnight. Inserts
were then loaded into custom-designed flow chambers
and subjected to 30 dynes/cm of shear stress for 3 h,
whereupon inserts were washed in PBS and immersed in
SYTO 16 green fluorescent nucleic acid stain (Life Tech-
nologies, Carlsbad, CA). Cells seeded onto inserts but
not subjected to flow were used as growth rate controls.
A Nikon Eclipse epifluorescence microscope was used to
capture nine low magnification fields/insert and nuclei
were counted in ImageJ. The average number of at-
tached cells was then expressed as a percentage of the
no-flow controls.
Measurement of cell motility
GBM cell motility was measured using a fluorescence
bead phagokinetic assay [26] as previously described
[1]. Briefly, wells of a six-well dish were coated with
poly-D-lysine, whereupon 1 μM diameter fluorescent
polystyrene microspheres (ThermoFisher Scientific,
Grand Island, NY), adjusted to a concentration of
0.018% v/v in PBS were added and allowed to adhere to
the poly-lysine for 2 h. Cells were plated in complete
tissue culture medium (TCM) at a cell/area density of 4
cells/mm2. Experiments were performed either in
DMSO or in 1 μm PD0325901. Experiments were also
performed with PD0325901-treated cells incubated in
hFn 7.1, a mouse monoclonal anti-human fibronectin
antibody, or with non-specific mouse IgG. Motile cells
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phagocytose beads as they move leaving behind non-
fluorescent tracks. Cleared area was quantified in
ImageJ.
Measurement of aggregate dispersal velocity
50–100 μm diameter aggregates of DMSO or PD0325901-
treated GBM-1-4 were deposited into 12-well tissue cul-
ture plates containing 2mls of pre-warmed TCM. Plates
were incubated for eight h. Images were captured for
each aggregate every hour and diameter at each time
point was measured. Dispersal velocity (DV) was repre-
sented by the slope as determined by linear regression
analysis for change of diameter as a function of time.
Only regression lines with r2 values of 0.95 and greater
were used to calculate DV for each GBM line. Data
were normalized with initial aggregate diameter. Twelve
aggregates were used to generate an average DV for
each GBM line.
Measurement of z-axis dispersal distance by confocal
microscopy
Dispersal of GBM cells through a NHA-seeded porous
filter was measured as previously described [1]. Two-
hundred μm thick, cross-linked polystyrene scaffolds
(Alvetex, Reinnervate, Durham, UK) with tunnel diame-
ters of 8–13 μm were seeded with 1x106 NHA cells in
100 μL of tissue culture medium. After 60 min to allow
NHA cells to adhere, scaffolds were placed in 12-well
plates and incubated in 4mls of TCM for 48 h to permit
incorporation of NHA cells throughout the scaffold.
After 48 h, GBM cells that had been transfected with
BacMam 2.0 GFPT (Life Technologies, Long Island, NY)
were deposited onto each scaffold in a small volume of
medium. Scaffolds were incubated for 48 h to allow time
for tumor cells to infiltrate and disperse. To image dis-
persed cells, a Yokogawa CSU-X1 spinning disk confocal
microscope with MetaMorph software was used to gener-
ate z-stacks of images taken at 1 μm intervals. Differential
interference contrast microscopy was used to identify the
z = 0 starting point for each z-stack. The z-axis position of
each cell within each tissue-scaffold was scored. Within
any given scaffold the mean average z-axis cell position
from 5– 6 z-stacks was measured and recorded.
Measurement of cell growth in conventional 2D culture
and in 3D spheroids
For measurement of growth in conventional 2D cultures,
cells were plated at a concentration of 5x104 cells/ml in
wells of a 6-well dish in complete medium. Total and
live cell counts were performed once/day for 4 days
using a BioRad TC10 automated cell counter. For meas-
urement of growth rate by 3D spheroids, aggregates
were generated using the hanging drop method [1]. Sin-
gle aggregates were plated onto wells of an agarose-
coated 6-well dish. Agarose prevented aggregates from
adhering to the bottom of the dish. The area of each ag-
gregate was measured once/day for nine days. Growth
rate was determined by plotting aggregate area as a
function of time. Regression analysis was performed to
calculate growth rates of 3D spheroids [1].
Results
Effects of PD0325901 on FNMA, actin organization
and pFAK localization in primary GBM cells
Studies have previously demonstrated a growth-
inhibitory role for PD0325901 in GBM [20]. Here, we
explore another potential role as a suppressor of GBM
dispersal. We first confirmed that the primary lines used
in this study are sensitive to drug treatment. Figure 1a
shows that PD0325901 treatment down-regulates p-
ERK, the downstream effector of MEK, in all 4 primary
GBM cell lines. Unlike Dex, PD0325901 did not induce
FNMA (Fig. 1c) relative to DMSO controls (Fig. 1b). Ra-
ther, treatment resulted in a remarkable change in cell
shape, treated cells (Fig. 1e) becoming flatter and larger
than those treated with DMSO (Fig. 1d). PD0325901
treatment also gave rise to the organization of actin into
stress fibers when cells were grown as conventional 2D
culture (Fig. 1d, e), and a shift in actin organization from
cortical to stress fibers when cells were incubated as 3D
hanging drops (Fig. 1h, i). Moreover, PD0325901 treat-
ment resulted in the localization of p-FAK at sites of
cell-ECM attachment (Fig. 1g). These results indicate
that PD0325901 treatment activates mechanisms in-
volved in regulating cell motility and mechanical proper-
ties of single cells or cellular aggregates.
The effects of PD0325901 on spheroid mechanical
properties are fibronectin dependent
We first generated measurements of aggregate cohesion
for GBM-1-4 treated in either DMSO or PD0325901,
and confirmed that the cohesion measured was reflective
of a true tissue surface tension (Table 1). We demon-
strated that all GBM samples exhibited the defining
characteristics of liquid-like behavior: (1) they display a
constant surface tension when subjected to two different
degrees of compression. Accordingly, the means of σ1
and σ2 when compared by a paired t-test are not signifi-
cantly different, (2) the ratio of σ2/σ1 approaches 1 and
is less than the ratio of the applied force at each succes-
sive compression (F2/F1). Table 1 shows that for all lines,
a t-test comparing the ratios of σ2/σ1 to F2/F1 resulted in
a p < 0.0001, indicating that the ratio of σ2/σ1 was sig-
nificantly different than that of F2/F1, and 3) the surface
tension of the aggregates is independent of aggregate
volume. For the 4 GBM lines, combined aggregate vol-
umes were plotted as a function of surface tension. Lin-
ear regression analysis yielded correlation coefficients,
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r2, of 0.031 and 0.071 for DMSO and PD0325901 treated
aggregates, respectively, indicating that surface tension is
independent of volume (Additional file 1: Figure S2).
Figure 2a shows that PD0325901 treatment did not have
an effect on aggregate surface tension. Surprisingly, how-
ever, generation of 3D spheroids in the presence of
300 μg/ml of serum fibronectin (sFn) resulted in a sig-
nificant increase in aggregate cohesion (Fig. 2b),
suggesting that the effects of PD0325901 may be
through enhancement of α5β1 integrin-fibronectin inter-
action. Since actin is a fundamental mediator of cell and
tissue mechanics, we reasoned that PD0325901 mediated
changes in actin reorganization should result in a change
in aggregate stiffness and viscosity. Interestingly, for ag-
gregates generated in 30 μg/ml sFn (30 sFn), PD0325901
treatment slightly increased stiffness (Fig. 2c) but had no
effect on viscosity (Fig. 2d). However, when aggregates
were generated in the presence of 300 μg/ml sFn, both
stiffness (Fig. 2c) and viscosity (2D) markedly increased.
This suggests that fibronectin is an absolute requirement
for PD0325901 to alter mechanical properties.
PD0325901 increases resistance to shear-stress induced
detachment, decreases cell motility and reduces dispersal
velocity
The effects of PD0325901 on cell shape, actin reorganization
and aggregate viscoelasticity translate to significant
changes in tumor cell behavior. Notably, PD0325901
treatment rendered GBM cells more resistant to shear-
induced detachment (Fig. 3a), suggesting a stabilization
of cell-ECM adhesion and a decrease in area cleared by
motile cells in a phagokinetic microbead assay. For all
lines, cleared area was reduced approximately 3-fold in
response to PD0325901 treatment, indicating a signifi-
cant decrease in cell motility. When experiments were
performed in TCM containing 5 μg/ml mouse mono-
clonal anti-human fibronectin antibody, the motility of
PD0325901-treated cells was restored to levels compar-
able to those of DMSO controls (Fig. 3b). This effect
was not observed when a non-specific mouse IgG was
used (Additional file 1: Figure S4). These results indicate
that the principal mechanism of PD0325901-mediated de-
crease in motility is α5β1 integrin-fibronectin dependent.
Collectively, the observed increase in attachment strength
to substrate and decreased motility gave rise to a signifi-
cant overall decrease in aggregate dispersal velocity.
Figure 3c shows that spheroids of GBM cells differ in
baseline dispersal velocities and that PD0325901 treat-
ment reduces DV relative to DMSO controls.
PD0325901 significantly alters pattern of dispersal and
z-axis penetration
Treatment with the MEK inhibitor also resulted in a
change in the pattern of dispersal. Whereas, the advancing
edge of DMSO-treated aggregates dispersed as single cells
(Fig. 4a, c), the leading edge of PD0325901-treated aggre-
gates advanced as a sheet (Fig. 4b, d). Moreover, actin in
advancing cells of DMSO-treated aggregates appeared to
be cortical (Fig. 4b), whereas in treated aggregates, actin
was arranged in stress fibers (Fig. 4d). This change in
spreading behavior is likely associated with reduced cell
motility, causing cells escaping the aggregate mass to
Fig. 1 Effects of PD0325901 on FNMA, actin organization and pFAK
localization in primary GBM cells. Immunoblot analysis for phosho-ERK
and ERK in response to overnight treatment with 1 μm PD0325901
or DMSO as vehicle control. PD0325901 significantly inhibited
phosphorylation of ERK (a). Representative immunofluorescence
images of FNMA by GBM-3 cells treated either with DMSO (b) or
PD0325901 (c). Fibronectin is depicted in green and DAPI (blue)
was used as counterstain. PD0325901 did not appear to induce
FNMA by GBM-3 cells. Rhodamine-phalloidin staining of actin in
DMSO-treated (d) or PD0325901-treated GBM-3 cells (e). Note significant
cell shape change and actin fiber organization. Scale bar in (e) is 5 μm.
Triple stain for actin (red), p-FAK (green) and DAPI (blue) in DMSO-treated
(f) and PD0325901-treated (g) GBM-3 cells. PD0325901 appears to induce
the localization of p-FAK at sites of cell-ECM attachment. Thirty-micron
thick z-stack of DMSO (h) and PD0325901-treated (i) collected by
confocal microscopy of multicellular aggregates of GBM-3. Note
marked change in actin organization from cortical to stress fibers.
Scale bar in (i) is 30 μm
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accumulate behind the advancing front. PD0325901 treat-
ment also resulted in a significant reduction in z-axis dis-
persal for three of the four lines (Fig. 4e). The z-axis
dispersal distance of PD0325901-treated GBM-1 and
GBM-2 cells was approximately 2-fold less than that of
the vehicle controls. GBM-3 cells responded more ac-
tively, their z-axis dispersal distance becoming reduced
approximately 13-fold relative to controls.
PD0325901 reduces growth rates of conventional 2D
cultures and 3D spheroids of GBM cells
Previous studies demonstrated that the growth rate of
various immortalized GBM cell lines was markedly re-
duced by PD0325901 [20]. We tested our primary GBM
lines to determine whether treatment had a similar effect
when cells were grown as conventional 2D cultures and
as spheroids. Figure 5 (a, b) shows that PD0325901
Table 1 Tissue surface tension measurements and confirmation of liquidity for DMSO-treated and PD0325901 treated aggregates of
primary GBM cells
Line σ1 dynes/cm ± s.e.m σ2 dynes/cm ± s.e.m σ1,2 dynes/cm ± s.e.m t-test σ1 vs σ2 p σ2/σ1 F2/F1 t-test σ2/σ1
vs F2/F1 p
GBM-1 DMSO 16.9 ± 1.9 19.4 ± 2.3 18.2 ± 1.5 0.4082 1.14 ± 0.05 1.36 ± 0.01 0.0003
GBM-1 PD03 18.4 ± 1.3 17.9 ± 1.2 18.1 ± 0.9 0.7951 0.98 ± 0.04 1.36 ± 0.02 <0.0001
GBM-2 DMSO 15.5 ± 1.4 16.9 ± 2.0 16.2 ± 1.2 0.5638 1.07 ± 0.08 1.35 ± 0.03 0.0072
GBM-2 PD03 15.2 ± 1.4 15.1 ± 1.0 15.2 ± 0.8 0.9035 1.02 ± 0.07 1.37 ± 0.04 0.0003
GBM-3 DMSO 8.5 ± 0.6 8.6 ± 0.7 8.6 ± 0.4 0.9041 1.01 ± 0.04 1.36 ± 0.02 <0.0001
GBM-3 PD03 8.9 ± 0.7 10.1 ± 0.6 9.5 ± 0.5 0.2389 1.15 ± 0.03 1.42 ± 0.07 0.0017
GBM-3 DMSO 300 FN 7.5 ± 0.7 7.1 ± 0.7 7.3 ± 0.5 0.6725 0.95 ± 0.03 1.28 ± 0.03 <0.0001
GBM-3 PD03 300 FN 32.7 ± 5.8 37.9 ± 6.6 35.3 ± 4.3 0.5550 1.17 ± 0.03 1.32 ± 0.03 0.0047
GBM-4 DMSO 16.2 ± 1.8 15.8 ± 1.2 16.0 ± 1.1 0.8833 1.01 ± 0.05 1.34 ± 0.01 <0.0001
GBM-4 PD03 20.6 ± 1.2 20.2 ± 1.0 20.4 ± 1.8 0.8312 1.02 ± 0.04 1.35 ± 0.02 <0.0001
For all cell lines, PD0325901 treatment did not result in a change in surface tension (pair-wise comparison by Student t-test, p > 0.05). GBM-3 was used to determine
effects of exogenous fibronectin on surface tension. Here, addition of 300 μg/ml of soluble fibronectin resulted in a significant increase in aggregate surface tension
(σ1,2) of 7.3 ± 0.5 to 35.3 ± 4.3 dynes/cm (pairwise Student t-test, p < 0.0001). Liquid behavior was confirmed by demonstrating that 1) surface tension measured at two
different compressions, the second greater than the first, were not statistically different, and 2) that the ratio of σ2/σ1 approaches 1 and is less than the ratio of the
applied force at each successive compression (F2/F1)
Fig. 2 Assessment of aggregate cohesion, stiffness, and viscosity in response to PD0325901 treatment. Surface tension measurements for GBM-1-4
aggregates generated using standard TCM and treated with either DMSO or PD0325901. n = 20, pair-wise comparison by Student t-test, p > 0.05 (a).
Surface tension measurements of GBM-3 aggregates generated in fibronectin-depleted medium supplemented with 300 μg/ml of human fibronectin.
n = 20, pair-wise comparison by Student t-test, p < 0.0001 (b). Stiffness (c) and viscosity (d) data for GBM-3 aggregates generated in fibronectin-
depleted medium supplemented with either 30 μg/ml or 300 μg/ml human fibronectin. Asterisks represent statistical significance by pair-wise Student
t-test, p < 0.05. Note significant increase in stiffness and viscosity in response to increased concentrations of fibronectin
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significantly decreases the growth rate of conventional
2D cultures of GBM-1-4 as compared to DMSO con-
trols. We then repeated the experiment using spheroids
of GBM cells. Figure 5c-f shows that PD0325901 treat-
ment significantly reduced the growth rate of GBM ag-
gregates since the slope of the growth curves was
significantly reduced by treatment relative to that of
controls. Linear regression analysis of the 3D growth
curves revealed a 2–11 fold reduction in growth rate
when spheroids of GBM cells were treated with the
drug. In fact, PD0325901 treated aggregates appeared to
decrease in size over time. This suggests that cells are ei-
ther dying and sloughing off the surface of the aggregate
– this was not observed for aggregates incubated for
Fig. 3 PD0325901 increases resistance to shear-stress induced
detachment, decreases cell motility, and reduces aggregate dispersal
velocity. Untreated and PD0325901-treated GBM cells attached to PET
membranes were subjected to 30 dynes/cm of shear flow for 3 h,
whereupon the number of cells retained on the membranes was
quantified. For GBM-1, GBM-2 and GBM-4, PD0325901 treatment
resulted in a significant retention of cells (a). A fluorescent
microbead phagokinetic track assay was used to measure cell
motility. For all GBM lines, PD0325901 significantly decreased
cleared area. Co-incubation of cells with PD0325901 and 5 μg/ml
anti-human fibronectin antibody, hFN 7.1, restored motility to control
levels. Asterisks represent statistical difference using ANOVA, p < 0.0001,
and Tukey’s multiple comparisons tests (b). The dispersal velocities of
PD0325901-treated aggregates (n = 24) was significantly lower than
those measured for PD0325901-treated aggregates (n = 24, c). For
Fig. 3a and c, asterisks represent significant difference at p < 0.05 by
pair-wise comparison using Student t-test
Fig. 4 PD0325901 significantly reduces aggregate spreading and ex
vivo dispersal. Aggregates of GBM-3 cells were plated onto tissue
culture plastic in complete medium with DMSO (a, c) or PD0325901
(b, d) and incubated for 24 h, whereupon they were fixed, permeabilized
and stained with rhodamine-phalloidin. Low Mag (a, b) and High Mag
(c, d) images were collected. Note single cell dispersal from un-
treated aggregates (a, c), in contrast to a higher level of cell-cell
contact and actin stress fibers in response to PD0325901 treatment.
(b, d). Scale bars in (a) and (c) are 100 μm. For GBM-1-3, PD0325901
decreased z-axis dispersal of GBM cells through a normal human
astrocyte seeded 3D scaffold (e). Asterisks represent pair-wise
comparison, Student t-test p < 0.05. No significant difference in
z-axis dispersal was observed for GBM-4 (p = 0.9731)
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2 days (Additional file 1: Figure S3, panel a) or 4 days
(Additional file 1: Figure S3, panel b) on agarose plates –
or that aggregates became more compact over time. This
appears to be the case inasmuch as PD0325901 treat-
ment resulted in more compact aggregates (Additional
file 1: Figure S3, Panel c). It is likely that the observed
compaction was due to overall contraction of cell size.
Discussion
Therapies aimed at containing tumor cell dispersal could
provide a powerful path towards extending the time of
disease-free and overall survival of glioblastoma patients.
Identifying drugs that can target molecular pathways in-
volved in dispersal would provide valuable insight to-
wards this goal. Our previous studies showed that
Dexamethasone, an FDA approved drug to treat tumor-
related edema in GBM, can also decrease in vitro and ex
vivo dispersal of primary human GBM cells. It does so
by activating α5β1 integrin and subsequent restoration
of FNMA and re-organization of cortical actin into
stress fibers. In turn, these changes engender an increase
in the strength of intercellular cohesion, increased at-
tachment of tumor cells to substrate, and reduced cell
motility. The net effect is an overall reduction in disper-
sal [1, 27]. The effects of Dex, however, are pleiotropic
and the drug likely targets many pathways, which in part
may explain the many side-effects associated with Dex
treatment. Identifying drugs that are more specific in
their targeting of dispersal-related pathways is therefore
important.
In this study, we explore whether inhibition of the
MAPK/ERK pathway, a critical regulator of processes
underlying invasion and metastasis [28], could have
similar effects on GBM dispersal. We tested the effects
of the MEK inhibitor, PD0325901, on 4 primary GBM
cell lines that were previously used to assess the effects
Fig. 5 PD0325901 reduces growth rates of conventional 2D cultures and 3D spheroids of GBM cells. Growth rate for conventional 2D cultures of
the GBM lines was measured either in DMSO (a) or PD0325901 (b). Fifty-thousand cells were plated and proliferation was monitored over a 4-day
period. PD0325901 treatment significantly reduced the growth rate of 2D cultures. Aggregates (n = 6 for each line and treatment) of GBM-1 (c),
GBM-2 (d), GBM-3 (e) and GBM-4 (f) were cultured either in the absence or presence of PD0325901 and area was measured for each aggregate
once/day for 9 days. Linear regression was used to analyze the data. Only regression lines with an r2 of 0.95 or higher were used. Regression lines
depicted are average area as a function of time. Growth rate was significantly reduced by PD0325901 for all GBM lines as demonstrated by a
significant shallowing of the slope of the line (ANCOVA, p < 0.0001). For GBM-1-4, growth rate was reduced 11.6, 2.7, 2.9, and 2.5-fold, respectively
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of Dex on dispersal [1, 21]. Studies have shown that cer-
tain GBM lines do not respond to MEK inhibitors [20].
We therefore assessed whether our lines are responsive
to PD0325901 by determining whether treatment results
in a decrease in the levels of phospho-ERK. All 4 lines
responded to the drug. We previously established that
the cell lines were all deficient in their capacity for
FNMA [1]. In contrast to Dex, treatment with
PD0325901 did not result in a significant increase in
FNMA. However, treatment with the MEK inhibitor re-
sulted in a remarkable change in cell shape and in the
reorganization of actin from cortical into stress fibers.
This was particularly evident when actin was visualized
in 3D spheroids. Given that the actin cytoskeleton is a
fundamental mediator of cell and tissue stiffness [29], we
posited that a shift in actin organization would corres-
pond to a change in tissue stiffness.
Stiffening of the ECM is considered to be a hallmark
of fibrotic lesions and has been demonstrated to modu-
late cell invasion and migration [30]. The current study
focused on whether aggregate stiffness and viscosity
could modulate dispersal. We quantified stiffness and
viscosity using methods based on ellipsoid relaxation,
specifically after the deforming external force is removed
[31, 32]. The aggregate was modeled as a Kelvin-Voigt
viscoelastic body [33, 34]. Unexpectedly, PD0325901
treatment only resulted in a modest increase in aggre-
gate stiffness but not of viscosity. However, when aggre-
gates were generated in higher concentrations of
fibronectin, both stiffness and viscosity increased signifi-
cantly. This is important for several reasons. First, the
fibronectin gene has been shown to be up-regulated in
GBM [35]. Accordingly, tumors able to respond to
PD0325901 and in the presence of high concentrations
of fibronectin, could, in principle, become stiffer and
more viscous. Stiffer tumors have previously been shown
to be less invasive and to grow more slowly [36]. Few
studies have addressed the issue of tumor viscosity and
those that have focus on applications of magnetic reson-
ance elastography in liver tumors where fibrosis is a key
parameter. In those studies, tumor viscosity appeared to
be higher in malignant tumors [37]. In GBM, however,
fibrosis is not typically observed. In GBM spheroids, the
increase in viscosity in response to PD0325901 treat-
ment was likely due to higher binding energy between
the activated α5β1 integrin and fibronectin. This would
effectively increase the friction between cells and the
ECM. This increase in friction could significantly reduce
the capacity for dispersal of tumor cells from the pri-
mary mass.
Treatment also resulted in the localization of p-FAK at
sites of cell-substrate attachment. This is consistent with
the observed resistance to flow-induced substrate de-
tachment of GBM cells, and to decreased motility. Since
cells require intermediate levels of cell-ECM adhesion to
be optimally motile [38], an increase in the strength of
cell-ECM adhesion past this point might stabilize adhe-
sion to substrate to a point that significantly reduces cell
movement, and consequently, dispersal. Decreased mo-
tility also appears to be associated with a significant
decrease in dispersal velocity of GBM aggregates. Since
PD0325901 treatment did not restore FNMA, it is likely
that decreased motility rather than increased cohesion is
the physical mechanism that restrains the detachment of
tumor cells from the mass. Indeed, cells at the leading
edge of treated aggregates appear to attach tightly to
substrate causing cells behind them to pile up, again
pointing to reduced motility as the primary restraint for
detachment. For three of the four primary GBM lines,
PD0325901 also significantly reduced the ability of single
GBM cells to disperse through an astrocyte-seeded scaf-
fold. It is not possible to differentiate between the effects
of PD0325901 on decreased motility and ability to dis-
perse through the scaffold, however, it is possible that on
a single cell level, the re-organization of actin into stress
fibers may have effectively rendered cells less compliant
and inhibited their capacity to sufficiently deform and
squeeze through pores established by the physical envir-
onment established by the scaffold. It is important to
note that for GBM-4, treatment did not reduce z-axis
dispersal. It is possible that in this line, compliance was
not effected by treatment, thus allowing cells to pene-
trate into the scaffold.
Lastly, MEK inhibitor treatment also appears to sig-
nificantly reduce growth rate of these primary GBM
lines in both conventional 2D and in 3D cultures. Other
studies have demonstrated in vivo efficacy of PD0325901
in reducing tumor growth in preclinical orthotopic
models of glioblastoma [18]. Our study provides compel-
ling evidence that PD0325901 can also reduce dispersal.
Growth and dispersal contribute significantly to recur-
rence. Accordingly, the drug has the potential to signifi-
cantly delay the onset of recurrence in GBM.
Identifying agents that can contain the primary or
recurrent tumor could significantly improve targeted de-
livery of chemotherapeutic agents and increase the likeli-
hood of total surgical resection. We have previously
identified Dexamethasone (Dex) as a potential candidate
to reduce dispersal of GBM [1]. Interestingly, the doses
required to elicit a dispersal inhibitory response are sig-
nificantly lower than those typically used to reduce
edema [1]. Clinically, MEK inhibitors are generally well
tolerated. Commonly occurring toxicities include rash,
diarrhea, fatigue, peripheral oedema and acneiform
dermatitis. Life-threatening toxicities associated with
MEKi are extremely rare. Long-term use is possible pro-
viding that adverse events are monitored and dose or
treatment schedules are modified, as required [39]. The
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measureable outcome for MEK inhibitor studies focus
on their ability to reduce tumor size. Here, we show an
added benefit of one MEK inhibitor as a potential de-
terrent of tumor cell dispersal. Whereas Dexametha-
sone readily crosses the blood–brain barrier, some
MEK inhibitors, including trametinib, have demon-
strated limited brain distribution due to association
with the P-glycoprotein efflux transporters found at the
blood–brain barrier [19]. Perhaps a strategy in which
MEK inhibitors are used as interstitial chemotherapy,
followed by continued administration of low-dose Dex,
could significantly improve prognosis of this devastat-
ing disease.
Conclusions
This study demonstrates that it is possible to impede dis-
persal of GBM by inhibiting the MAPK/ERK pathway
using the MEK inhibitor PD0325901. To our knowledge,
this is the first demonstration that the drug can also im-
pede GBM dispersal. Containing the primary or recurrent
tumor by interstitial administration of MEK inhibitors
could significantly improve delivery of chemotherapeutic
agents and increase the likelihood of total surgical resec-
tion. This could significantly extend the time of disease-
free and overall survival of glioblastoma patients.
Additional file
Additional file 1: Analytical method for measurement of aggregate
viscoelasticity. (DOCX 58681 kb)
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